Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced positive additional data from the phase III (POISE) study on obeticholic acid (OCA) being developed for the treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares after opening at $247.48 moved to $287.00 on last trade day and at the end of the day closed at $282.77. Company price to sales ratio in past twelve months was calculated as 3555.83 and price to cash ratio as 39.26. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) showed a positive weekly performance of 10.46%.
One such stock that you may want to consider dropping is Retrophin, Inc. (NASDAQ:RTRX) which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Retrophin Inc. (NASDAQ:RTRX) shares advanced 7.00% in last trading session and ended the day on $14.83. RTRX return on equity ratio is recorded as – and its return on assets is -707.30%. Retrophin Inc. (NASDAQ:RTRX) yearly performance is 104.55%.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported a net loss of $69.4 million for the year ended December 31, 2013. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares moved up 5.34% in last trading session and was closed at $8.48, while trading in range of $7.91 – $8.63. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) year to date (YTD) performance is -34.87%.
For the fourth quarter of 2013, Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) reported a net loss of $7.6 million versus a net loss of $4.4 million in the comparable period in 2012. For the year ended December 31, 2013, Auspex reported a net loss of $15.6 million compared to $15.1 million for the same period in 2012. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) weekly performance is -13.68%. On last trading day company shares ended up $22.91. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is -16.64%. Analysts mean target price for the company is $38.50.